{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:51:57Z","timestamp":1787068317439,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00115-021-01221-x","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T11:02:52Z","timestamp":1636023772000},"page":"234-242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ketamin und andere N-Methyl-D-Aspartat-Rezeptor-Modulatoren zur Behandlung der Depression","Ketamine and other N-methyl-D-aspartate receptor modulators in treatment of depression"],"prefix":"10.1007","volume":"93","author":[{"given":"Stefan","family":"Vestring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Domschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Normann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"1221_CR1","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","volume":"278","author":"A Bahji","year":"2021","unstructured":"Bahji\u00a0A, Vazquez\u00a0GH, Zarate\u00a0CA (2021) Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J\u00a0Affect Disord 278:542\u2013555","journal-title":"J Affect Disord"},{"key":"1221_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman\u00a0RM, Cappiello\u00a0A, Anand\u00a0A et\u00a0al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351\u2013354","journal-title":"Biol Psychiatry"},{"key":"1221_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","volume":"82","author":"D Bugarski-Kirola","year":"2017","unstructured":"Bugarski-Kirola\u00a0D, Blaettler\u00a0T, Arango\u00a0C et al (2017) Bitopertin in negative symptoms of schizophrenia-results from the phase III FlashLyte and DayLyte studies. Biol Psychiatry 82:8\u201316","journal-title":"Biol Psychiatry"},{"key":"1221_CR4","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","volume":"175","author":"CM Canuso","year":"2018","unstructured":"Canuso\u00a0CM, Singh\u00a0JB, Fedgchin\u00a0M et al (2018) Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a\u00a0double-blind, randomized, placebo-controlled study. Am J Psychiatry 175:620\u2013630","journal-title":"Am J Psychiatry"},{"key":"1221_CR5","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","volume":"184","author":"PC Casarotto","year":"2021","unstructured":"Casarotto\u00a0PC, Girych\u00a0M, Fred\u00a0SM et\u00a0al (2021) Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell 184:1299\u20131313","journal-title":"Cell"},{"key":"1221_CR6","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/mp.2017.61","volume":"22","author":"E Castr\u00e9n","year":"2017","unstructured":"Castr\u00e9n\u00a0E, Antila\u00a0H (2017) Neuronal plasticity and neurotrophic factors in drug responses. Mol Psychiatry 22:1085\u20131095","journal-title":"Mol Psychiatry"},{"key":"1221_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly\u00a0EJ, Trivedi\u00a0MH, Janik\u00a0A et al (2019) Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 76:893\u2013903","journal-title":"JAMA Psychiatry"},{"key":"1221_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","volume":"67","author":"N Diazgranados","year":"2010","unstructured":"Diazgranados\u00a0N, Ibrahim\u00a0L, Brutsche\u00a0NE et al (2010) A randomized add-on trial of an N\u2011methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793\u2013802","journal-title":"Arch Gen Psychiatry"},{"key":"1221_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","volume":"178","author":"A Feder","year":"2021","unstructured":"Feder\u00a0A, Costi\u00a0S, Rutter\u00a0SB et\u00a0al (2021) A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry 178:193\u2013202","journal-title":"Am J Psychiatry"},{"key":"1221_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1124\/jpet.116.239228","volume":"361","author":"K Fukumoto","year":"2017","unstructured":"Fukumoto\u00a0K, Toki\u00a0H, Iijima\u00a0M et al (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J\u00a0Pharmacol Exp Ther 361:9\u201316","journal-title":"J Pharmacol Exp Ther"},{"key":"1221_CR11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1085\/jgp.201812032","volume":"150","author":"KB Hansen","year":"2018","unstructured":"Hansen\u00a0KB, Yi\u00a0F, Perszyk\u00a0RE, Furukawa\u00a0H et\u00a0al (2018) Structure, function, and allosteric modulation of NMDA receptors. J\u00a0Gen Physiol 150:1081\u20131105","journal-title":"J Gen Physiol"},{"key":"1221_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40263-021-00816-x","volume":"35","author":"ID Henter","year":"2021","unstructured":"Henter\u00a0ID, Park\u00a0LT, Zarate\u00a0CA (2021) Novel glutamatergic modulators for the treatment of mood disorders: current status. CNS Drugs 35:527\u2013543","journal-title":"CNS Drugs"},{"key":"1221_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jad.2006.03.004","volume":"93","author":"U Heresco-Levy","year":"2006","unstructured":"Heresco-Levy\u00a0U, Javitt\u00a0DC, Gelfin\u00a0Y et al (2006) Controlled trial of D\u2011cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J\u00a0Affect Disord 93:239\u2013243","journal-title":"J Affect Disord"},{"key":"1221_CR14","unstructured":"FDA (2019) FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor\u2019s office or clinic. http:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified. Zugegriffen: 23. Aug. 2021"},{"key":"1221_CR15","unstructured":"Rote Liste (2021) Spravato\u00ae 28 mg Nasenspray, L\u00f6sung. https:\/\/www.arzneimitteltherapie.de\/_Resources\/Persistent\/59bea9c351233c50859eb2276db807de2701e8c6\/210222_Fachinformation%20Spravato.pdf. Zugegriffen: 23. Aug. 2021"},{"key":"1221_CR16","unstructured":"GBA (2021) Tragende Gr\u00fcnde. https:\/\/www.g-ba.de\/downloads\/40-268-7781\/2021-08-19_AM-RL-XII_Esketamin_D-659_TrG.pdf. Zugegriffen: 23. Aug. 2021"},{"key":"1221_CR17","first-page":"1","volume":"27","author":"MA Horowitz","year":"2020","unstructured":"Horowitz\u00a0MA, Moncrieff\u00a0J (2020) Are we repeating mistakes of the past? A review of the evidence for esketamine. Br J Psychiatry 27:1\u20134","journal-title":"Br J Psychiatry"},{"key":"1221_CR18","unstructured":"Cision (2020) NeuroRx: phase 3 drug for suicidal bipolar depression to present at BIO CEO conference. https:\/\/www.prnewswire.com\/news-releases\/neurorx-phase-3-drug-for-suicidal-bipolar-depression-to-present-at-bio-ceo-conference-301001882.html. Zugegriffen: 23. Aug. 2021"},{"key":"1221_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/2040622315579059","volume":"6","author":"ND Iadarola","year":"2015","unstructured":"Iadarola\u00a0ND, Niciu\u00a0MJ, Richards\u00a0EM et al (2015) Ketamine and other N\u2011methyl-D-aspartate receptor antagonists in the treatment of depression: a\u00a0perspective review. Ther Adv Chronic Dis 6:97\u2013114","journal-title":"Ther Adv Chronic Dis"},{"key":"1221_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4088\/JCP.14l09527","volume":"76","author":"JT Kantrowitz","year":"2015","unstructured":"Kantrowitz\u00a0JT, Halberstam\u00a0B, Gangwisch\u00a0J (2015) Single-dose ketamine followed by daily D\u2011cycloserine in treatment-resistant bipolar depression. J\u00a0Clin Psychiatry 76:737\u2013738","journal-title":"J Clin Psychiatry"},{"key":"1221_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3233\/JAD-161251","volume":"57","author":"T Kishi","year":"2017","unstructured":"Kishi\u00a0T, Matsunaga\u00a0S, Iwata\u00a0N (2017) A meta-analysis of memantine for\u00a0depression. J\u00a0Alzheimers Dis 57:113\u2013121","journal-title":"J Alzheimers Dis"},{"key":"1221_CR22","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1017\/S0033291716000064","volume":"46","author":"T Kishimoto","year":"2016","unstructured":"Kishimoto\u00a0T, Chawla\u00a0JM, Hagi\u00a0K et al (2016) Single-dose infusion ketamine and non-ketamine N\u2011methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a\u00a0meta-analysis of efficacy, safety and time trajectories. Psychol Med 46:1459\u20131472","journal-title":"Psychol Med"},{"key":"1221_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","volume":"271","author":"GC Leal","year":"2021","unstructured":"Leal\u00a0GC, Bandeira\u00a0ID, Correia-Melo\u00a0FS et al (2021) Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci 271:577\u2013582","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1221_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1017\/S0033291714001603","volume":"45","author":"A McGirr","year":"2015","unstructured":"McGirr\u00a0A, Berlim\u00a0MT, Bond\u00a0DJ et al (2015) A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 45:693\u2013704","journal-title":"Psychol Med"},{"key":"1221_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4088\/JCP.15r10334","volume":"78","author":"JF McGuire","year":"2017","unstructured":"McGuire\u00a0JF, Wu\u00a0MS, Piacentini\u00a0J et al (2017) A meta-analysis of D\u2011cycloserine in exposure-based treatment: moderators of treatment efficacy, response, and diagnostic remission. J\u00a0Clin Psychiatry 78:196\u2013206","journal-title":"J Clin Psychiatry"},{"key":"1221_CR26","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/npp.2013.150","volume":"38","author":"CI Rodriguez","year":"2013","unstructured":"Rodriguez\u00a0CI, Kegeles\u00a0LS, Levinson\u00a0A et al (2013) Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 38:2475\u20132483","journal-title":"Neuropsychopharmacology"},{"key":"1221_CR27","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1176\/appi.ajp.2019.19070688r","volume":"176","author":"AF Schatzberg","year":"2019","unstructured":"Schatzberg\u00a0AF (2019) More thoughts on intranasal esketamine: response to Drevets et\u00a0al. Am J Psychiatry 176:858\u2013859","journal-title":"Am J Psychiatry"},{"key":"1221_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1176\/ajp.122.5.509","volume":"122","author":"JJ Schildkraut","year":"1965","unstructured":"Schildkraut\u00a0JJ (1965) The catecholamine hypothesis of affective disorders: a\u00a0review of supporting evidence. Am J Psychiatry 122:509\u2013522","journal-title":"Am J Psychiatry"},{"key":"1221_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos\u00a0P, Moaddel\u00a0R, Morris\u00a0PJ et al (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533:481\u2013486","journal-title":"Nature"},{"key":"1221_CR30","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate","year":"2006","unstructured":"Zarate\u00a0CA, Singh\u00a0JB, Carlson\u00a0PJ et al (2006) A randomized trial of an N\u2011methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856\u2013864","journal-title":"Arch Gen Psychiatry"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01221-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-021-01221-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01221-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T08:28:20Z","timestamp":1646382500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-021-01221-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1221"],"URL":"https:\/\/doi.org\/10.1007\/s00115-021-01221-x","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"assertion":[{"value":"5 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Vestring gibt an, dass kein Interessenskonflikt besteht. K.\u00a0Domschke ist Mitglied des Neuroscience Steering Committee, Janssen-Cilag GmbH. C.\u00a0Normann erhielt Honorare von Janssen-Cilag GmbH f\u00fcr Advisory Boards, Vortr\u00e4ge und klinische Forschung.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}